News

Tibotec said it anticipates receiving the conditional marketing authorization from the European Commission by early next year. The positive opinion is based on the efficacy and safety results

The filing is based on the results of three trials of Tysabri assessing the safety and efficacy as both an induction and maintenance therapy. The filing also includes

Doripenem belongs to a class of antibacterial agents called carbapenems, which are useful in treating life-threatening infections caused by gram-positive and resistant gram-negative bacteria. Pseudomonas, a gram-negative bacterium,

Amoxicillin Pulsys has previously faced setbacks when the drug failed clinical trials. However a recent phase III trial of Amoxicillin Pulsys successfully met its primary and secondary endpoints.

Daronrix is intended for the prevention of influenza during a pandemic situation, once the pandemic viral strain has been included. The mock-up pandemic influenza vaccine is not expected

The payment was completed pursuant to the terms of the amended license agreement with Amarin Neuroscience. MultiCell estimates MCT-125 could generate up to $3 billion in cumulative worldwide

The study was led by researchers at Beth Israel Deaconess Medical Center (BIDMC), in collaboration with scientists at Columbia University Medical Center. In cases of chronic inflammation, certain

“We want to ensure that our application to the FDA is as robust as possible in an evolving regulatory environment and we are confident that the additional data

“This approval is another example of our agency’s efforts to increase access to safe and effective generic alternatives as soon as the law permits,” said Gary Buehler, director,